KEAP1 and early-onset autosomal dominant Alzheimer disease: A broad range of Nrf2 activators that target Keap1 and disrupt the Nrf2-Keap1 complex have been tested for neurodegenerative diseases including Huntington’s, Parkinson’s, Alzheimer’s diseases, and multiple sclerosis with promising results [164,165].